Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia

ConclusionIdelalisib 150  mg twice daily was considered tolerable in Japanese patients with follicular lymphoma or chronic lymphocytic leukemia.(Clinical trial registration: NCT02242045)
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research